ISPOR Europe Event 2024 at Barcelona, Spain

ISPOR Europe 2024

We are excited to be attending ISPOR Europe 2024 in Barcelona, Spain in November. Below you will find information on our attendees, details of our booth in the conference exhibition hall and a summary of research we are proud to have contributed to the conference. You’ll be able to access our insights on key topics via the link at the bottom of this page following the conference.

Visit Us

We will be located at Booth 700 within the main exhibition hall, where you’ll always be able to find someone from Costello Medical and learn more about our company and services. We look forward to meeting with you! If you would like to book a meeting with us ahead of time, please feel free to reach out to any of our attendees listed below or Get in Touch.

Who’s Attending

We’re delighted to have a team of 22 people attending the conference, including experts in our evidence development (literature reviews and synthesis and real-world evidence), market access and health economics services, as well as representatives from our dedicated MedTech, rare diseases and health policy-focused teams. We also have a dedicated representative from our Technical Innovation and Development team.

Value & Access

  • Matt Griffiths – Global Head of HTA
  • Alex Porteous – Deputy Head of HTA
  • Fern Woodhouse – Consultant, HTA
  • Elizabeth Parke – Senior Analyst, HTA
  • Cat Bunting – UK Head of Market Access
  • Helen Bewicke-Copley – Consultant, Market Access
  • Ellie Atkinson – Senior Analyst, Market Access
  • Naman Kochar – Senior Analyst, Pro Bono
  • Amrita Viswambaram – Deputy Division Head, APAC Market Access and Health Economics

Evidence Development

  • Naomi van Hest – UK Head of Health Economics and Statistics
  • Thomas Kloska – Senior Health Economist
  • Andrei Karlsson – Senior Statistician
  • Cameron Costello – Consultant, RWE
  • Siddharth Ramanan – Senior Analyst, RWE
  • Hannah Luedke – Consultant, Literature Reviews and Synthesis
  • Emma Worthington – Senior Analyst, Literature Reviews and Synthesis

MedTech

  • Ben McNally – Head of MedTech
  • Alex Pashley – Senior Consultant

Rare Diseases

  • Issy Newell – Deputy Head of Rare Diseases
  • Kate Hanman – US Head of Rare Diseases

Health Policy

  • Jamie Doorbar – Senior Analyst

Technical Innovation and Development

  • Saarang Tiwari – Technical Innovation and Development Lead

We will have a number of key focuses for the conference, including Joint Clinical Assessment and the potential for technical innovation and artificial intelligence (AI) to facilitate advances in health economics and outcomes research (HEOR).

Joint Clinical Assessment

The Health Technology Assessment (HTA) landscape in Europe is undergoing a significant shift, with the introduction of the Joint Clinical Assessment (JCA) as part of the European Union’s Regulation on HTA (HTAR; 2021/2282). JCA will be introduced in 2025, initially for oncology products and advanced therapy medicinal products, with expansion to orphan products in 2028 and all new medicines in 2030.

Our teams across Value & Access and Evidence Generation have been reflecting on the key challenges and opportunities, and have published a series of articles available here, including considerations for systematic reviews, evidence synthesis, value dossiers, and completion of the JCA submission template. We are pleased to present a number of JCA-focused research topics at the conference, which are summarised below.

If you have any questions about how we are preparing for JCA please don’t hesitate to reach out to Matt Griffiths or any of our other conference attendees.

Technical Innovation and AI

The potential for technical innovation and AI to facilitate advances in HEOR is an important research interest for us at Costello Medical, and we are excited to engage in sessions that delve into this topic at ISPOR Europe 2024.

Our teams across Value & Access and Evidence Generation have conducted pilots to explore opportunities for innovation, including the use of generative AI (GenAI) to support value dossier development and insight gathering to inform HTA strategy. We are also excited to present research at the conference summarising our pilot to develop and test AI-generated PICOs summaries to aid in literature reviews.

If you have any questions about our AI strategy, or would be interested in collaborating with us, please don’t hesitate to reach out to Helen Chambers or any of our conference attendees.

Issue Panels

We are delighted to be running two issue panels at ISPOR Europe 2024, Barcelona. The details of each session can be found below.

 

Is It Time for More Non-Profits to Lead Reimbursement and Commercialisation of Gene Therapies to Promote Affordable and Sustainable Access?

Following withdrawals of gene therapies by for-profit manufacturers, Kate will moderate an issue panel discussing whether non-profit-led gene therapy development and commercialisation could promote more affordable and sustainable access, exploring commercial challenges, patient perspectives and resource requirements needed to navigate the upcoming mandatory EU JCA.

  • Date: Tuesday, 19 November
  • Session Time: 13:45–14:45
Panel image of Kate Hanman

 

Take My Word for It: Can Patient-Centric Social Listening Enrich RWE?

Siddharth will lead a discussion exploring social media listening (SML) as a medium of real-world data, the role of AI in SML analysis, acceptable use cases and evidence standards for use of SML in HTA.

  • Date: Wednesday, 20 November
  • Session Time: 10:00–11:00

 

Panel image of Siddharth Ramanan

Our Research Posters

We are delighted to present 16 research posters at ISPOR Europe 2024, Barcelona. The titles of our research are listed below, alongside the poster session dates and times.

Joint Clinical Assessment

Monday, 18 November

HTA102: Are EU JCA Evidence Requirements Achievable? Insights From a Retrospective Evidence Analysis Study for Rare and Non-Rare EU Treatment Landscapes

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

 

Tuesday, 19 November

PT25: Potential for Standardization in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer

This poster has been selected for a poster tour given the particularly high impact nature of the research conducted.

  • Poster Session: 10:30–13:30
  • Discussion Hour: 11:30–12:15

HTA216: Navigating Prospective PICO Consolidation in Oncology: Insights From Retrospective Simulations for Crowded and Non-Crowded EU Treatment Landscapes

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA Processes

Monday, 18 November

HTA24: What Key Areas of Clinical and Economic Uncertainty Have Scottish Medicines Consortium (SMC) Identified in Ultra-Orphan Initial Assessments to Date?

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA85: Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

HTA90: The NICE Diagnostics Assessment Programme: Does Assessment Lead to Approval?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Evidence Development

Monday, 18 November

SA4: From Approval to Publication: Study Types and Timeframes using the UK Clinical Practice Research Datalink

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

 

Tuesday, 19 November

MSR107: Developing and Testing AI-Generated PICOs Summaries to Aid in Literature Reviews

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

MSR154: Comparison of Methods to Estimate Total Person-Time at Risk for Synthesis Studies of Incidence Rates in Observational Data

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Economic Evaluation

Monday, 18 November

HTA110: Acceptance of Cure Assumptions in NICE Oncology Technology Appraisals: Remission Impossible?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00-19:00

 

Tuesday, 19 November

EE354: An Exploratory Cost-Effectiveness Analysis of Cancer Vaccines in Combination With Current Immune Checkpoint Inhibitors Vs Immune Checkpoint Inhibitor Monotherapy: A Case Study for V940 in High-Risk Stage 3 Melanoma in the US

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA251: Investigating the Quantitative Effect of Integrating Environmental Impacts Into Economic Evaluations: To What Extent Could Environmental Sustainability Influence Decision Making in Health Technology Assessment?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Patient-Centred Research

Monday, 18 November

PCR61: Capturing the Real-World Patient Perspective in HTA: Expert Patient Insights Lead to Robust Healthcare Cost and Resource Use Inputs for Cost-Effectiveness Model in Spinal Muscular Atrophy

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA131: Opportunities for Patient Involvement in HTA in the Philippines: Lessons From Guidelines in Europe, North America, and the Asia-Pacific

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Health Policy

Monday, 18 November

SA25: Shaping Health Policy and Clinical Practice: A Critical Evaluation of Literature Review Methods in the Evidence Base

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

SA35: How Do Healthcare Professionals Perceive Delphi Panels and Use Study Outcomes?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Conference Reports

Our conference attendees will prepare commentaries on a variety of specific topics from ISPOR Europe 2024. Watch this space for the link to our commentaries soon after the conference!

Loading